WAYNE, Pa., Sept. 6, 2017
/PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"),
a fully integrated specialty pharmaceutical company focused on
developing, manufacturing and commercializing innovative treatments
for pain and other conditions, today announced that management will
be presenting at three investor conferences this fall. The
presentations are as follows:
- BioCentury Future Leaders
September 8, 2017 at 2:00
p.m.
Millennium Broadway Hotel & Conference Center in
New York, NY
For more information, visit
https://www.biocentury.com/conferences/future-leaders-2017.
- Cantor Fitzgerald Global Healthcare Conference
September 25, 2017 at 11:30 a.m.
InterContinental New York Barclay Hotel in New York, NY
For more information, visit
http://www.meetmax.com/sched/event_43201/~public/conference_home.html.
- The MicroCap Conference
October 5, 2017
The Essex House in New York,
NY
For more information, visit
http://microcapconf.com/conferences/new-york-2-2017/.
The investor presentations will be audio webcast live and
available for replay at Egalet's website at
http://egalet.investorroom.com/eventsandwebcasts.
About Egalet
Egalet, a fully integrated specialty
pharmaceutical company, is focused on developing, manufacturing and
commercializing innovative treatments for pain and other
conditions. Egalet has two approved products: OXAYDO®
(oxycodone HCI, USP) tablets for oral use only –CII and
SPRIX® (ketorolac tromethamine) Nasal Spray. In
addition, using its proprietary Guardian™ Technology, Egalet is
developing a pipeline of clinical-stage, product candidates that
are specifically designed to deter abuse by physical and chemical
manipulation. The lead programs, ARYMO™ ER, an
abuse-deterrent, extended-release, oral morphine formulation, and
Egalet-002, an abuse-deterrent, extended-release, oral oxycodone
formulation, are being developed for the management of pain severe
enough to require daily, around-the-clock, long-term opioid
treatment and for which alternative treatment options are
inadequate. Egalet's Guardian Technology can be applied broadly
across different classes of pharmaceutical products and can be used
to develop combination products that include multiple active
pharmaceutical ingredients with similar or different release
profiles. For additional information on Egalet, please visit
egalet.com. For full prescribing information on SPRIX, including
the boxed warning, please visit sprix.com. For full prescribing
information on OXAYDO, please visit oxaydo.com.
Safe Harbor
Statements included in this press release
(including but not limited to upcoming milestones) that are not
historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on management's current
expectations, and are subject to known and unknown uncertainties
and risks. Actual results could differ materially from those
discussed due to a number of factors, including, but not limited
to: the success of Egalet's clinical trials, including the timely
recruitment of trial subjects and meeting the timelines therefor;
Egalet's ability to obtain and maintain regulatory approval of
Egalet's products and product candidates and any regulatory
action involving Egalet's products; Egalet's ability to maintain
the intellectual property position of Egalet's products and product
candidates; Egalet's ability to identify and reliance upon
qualified third parties to manufacture its products; Egalet's
ability to service its debt obligations; Egalet's ability to find
and hire qualified sales professionals; the receptivity in the
marketplace and among physicians to Egalet's products; the success
of products which compete with Egalet's that are or become
available; general market conditions; and other risk factors
described in Egalet's filings with the United States Securities and
Exchange Commission. Egalet assumes no obligation to update or
revise any forward-looking-statements contained in this press
release whether as a result of new information or future events,
except as may be required by law.
Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 917-432-9275
View original content with
multimedia:http://www.prnewswire.com/news-releases/egalet-to-present-at-investor-conferences-this-fall-300514027.html
SOURCE Egalet Corporation